Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Thymosin α1 (Tα1) has been shown to improve survival in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), but its immunomodulatory mechanisms remain unclear. This study investigated how Tα1 restores immune homeostasis to confer a survival benefit in these patients. In this open-label, randomized controlled trial (NCT 03082885), 73 patients with HBV-ACLF received either standard medical therapy (SMT, n = 38) or SMT plus Tα1 (n = 35). Peripheral blood immune cell subsets were analyzed by flow cytometry and serum cytokine levels were measured by ELISA. Patients were stratified by 90-day transplant-free survival. Patients who survived at 90 days exhibited a higher proportion of effector T (TE) cells and lower levels of regulatory T cells (Tregs) at baseline compared to non-survivors. Survivors also had significantly higher initial levels of pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ) and lower levels of TGF-β. Over time, survivors showed a gradual decline in inflammatory markers, whereas non-survivors developed a progressive inflammatory storm. Tα1 treatment significantly increased 90-day transplant-free survival and was associated with reduced frequencies of Tregs and CD226low/– Treg subsets at weeks 4–8. Tα1 also moderated the late-stage hyperinflammatory response without compromising early immune activation. Tα1 improves clinical outcomes in HBV-ACLF by rebalancing the immune response—mitigating excessive inflammation and preventing immune paralysis by modulating T-cell differentiation and cytokine production, thereby breaking the cycle of hyperinflammation and immunosuppression that characterizes ACLF progression. Thymosin α1 modulates T-cell differentiation and cytokine production to rebalance the immune response, thereby disrupting the vicious cycle of hyperinflammation and immunosuppression in HBV-associated acute-on-chronic liver failure (HBV-ACLF).
Fields of Study & Subjects
Liver Disease and Transplantation
Hepatitis B Virus Studies
Sepsis Diagnosis and Treatment
Publication details
- Journal / source
- Figshare
- Publication date
- 27 March 2026
- Language
- EN